Intensive granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis.
Yoko MizutaniKento FujiiMiho KawamuraMadoka InoueYuki H MizutaniKanako MatsuyamaTomoaki DoiSoichiro NagayaMariko SeishimaPublished in: The Journal of dermatology (2020)
Granulocyte and monocyte adsorption apheresis (GMA) is usually performed weekly (consisting of five sessions) for refractory skin diseases, such as generalized pustular psoriasis (GPP). The time to remission of inflammatory bowel diseases has been reported to be significantly shorter in intensive GMA (twice a week) than in regular GMA (once a week). Despite several reports of GPP cases treated with intensive GMA, the efficacy of intensive GMA has not been verified in GPP. Herein, we present two GPP patients with a mutation in the IL36RN gene, who initially received regular GMA, and intensive GMA upon recurrence. There were no adverse effects during regular and intensive GMA for both patients. Because concomitant medication was only prednisolone (20 mg/day) during regular and intensive GMA, intensive GMA showed superiority to regular GMA in patient 1. Although concomitant medications were different between regular and intensive GMA in patient 2, these drugs had been used before the start of each GMA therapy. We cannot neglect the effects of concomitant drugs, but we observed a shorter time to remission in intensive GMA than that in regular GMA in both patients. More case studies will be necessary for evaluating the clinical efficacy of intensive GMA.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- clinical trial
- dendritic cells
- randomized controlled trial
- healthcare
- chronic kidney disease
- gene expression
- stem cells
- dna methylation
- prognostic factors
- genome wide
- peritoneal dialysis
- rheumatoid arthritis
- systemic lupus erythematosus
- bone marrow
- patient reported outcomes
- disease activity
- adverse drug